Ignite Creation Date:
2024-05-06 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03519529
Status:
COMPLETED
Last Update Posted:
2018-05-11
First Post:
2018-04-26
Brief Title:
Sex Hormone Binding Globulin Testosterone and Glycemic Control in Patients With Type 2 Diabetes
Sponsor:
Nanjing First Hospital Nanjing Medical University
Organization:
Nanjing First Hospital Nanjing Medical University
Study Overview
Official Title:
The Relationship Between Sex Hormone Binding Globulin Testosterone and Glycemic Control in Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sex hormone-binding globulinSHBG is a surrogate marker of insulin resistance This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetesT2D
Detailed Description:
The investigators recorded clinical factors biochemical criterion such as serum levels of glucose and lipids HbA1c SHBG testosterone insulin EPO C-peptide glucagon microalbuminuria glycemic variation via CGM carotid plaque ECG and ultrasonic cardiogram in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to Aprol 2018 The relationship between levels of SHBG testosterone and glycemic variationdiabetic complications are analysed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None